Elemol is a woody sesquiterpene alcohol found in elemi, hinoki leaf and twig oil, siam wood, guaiacwood, and related aromatic materials. The public evidence base is stronger than for many niche essential-oil constituents because identity sources are clear, a RIFM fragrance safety assessment exists, and preclinical studies report repellency and topical inflammation-model activity. That said, the functional literature remains preclinical, so AromaForge should position elemol as a chemistry-forward constituent with moderate safety coverage and early-stage bioactivity rather than as a proven wellness active.
Chemical identity and composition
PubChem resolves elemol as CID 92138 with formula C15H26O and CAS 639-99-6. Public sources and the archive both use the shorter name elemol and the variant alpha-elemol for the same constituent cluster, so this record should be read as substantially overlapping that naming family rather than as a separate chemistry. In local oil data, elemol is especially visible in hinoki false cypress leaf oil at 14.78%, elemi essential oil at 9.42%, and siam wood at 2.05%.
Aroma and practical use
- Use the recorded woody, sweet, floral, terpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2015 full-text study reported that elemol attenuated DNCB-induced AD-like skin lesions in BALB/c mice, lowered serum IgE, reduced mast-cell infiltration, and downregulated inflammatory cytokine expression while also reducing beta-hexosaminidase release in RBL-2H3 cells.
A 2015 full-text study reported that elemol attenuated DNCB-induced AD-like skin lesions in BALB/c mice, lowered serum IgE, reduced mast-cell infiltration, and downregulated inflammatory cytokine expression while also reducing beta-hexosaminidase release in RBL-2H3 cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A Springer abstract page reports that both amyris oil and isolated elemol repelled blacklegged and lone star ticks in laboratory bioassays, and that elemol did not differ significantly from DEET against Amblyomma americanum in one assay condition.
A Springer abstract page reports that both amyris oil and isolated elemol repelled blacklegged and lone star ticks in laboratory bioassays, and that elemol did not differ significantly from DEET against Amblyomma americanum in one assay condition.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A PubMed-indexed anti-mildew paper reported that elemol was among isolated compounds with strong anti-mildew activity in Calocedrus macrolepis var. formosana leaf-oil work, providing ecological and materials-use context rather than human-use evidence.
A PubMed-indexed anti-mildew paper reported that elemol was among isolated compounds with strong anti-mildew activity in Calocedrus macrolepis var. formosana leaf-oil work, providing ecological and materials-use context rather than human-use evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A 2017 RIFM fragrance ingredient safety assessment concluded that available use information did not indicate genotoxic, phototoxic, or photoallergenic concern for elemol under the assessment framework, and it reported exposure below the dermal sensitization threshold.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The same RIFM assessment reported no separate IFRA standard for elemol at the time of review and cited an average maximum concentration in hydroalcoholic products of 0.07%.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No constituent-specific human clinical efficacy study for isolated elemol was verified in this pass, so archive copy should avoid treatment-style claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
ige mast cell and cytokine downshift in ad model
A full-text elemol paper reported reduced serum IgE, reduced mast-cell infiltration, lower beta-hexosaminidase release, and lower expression of several inflammatory cytokines in cell and mouse atopic-dermatitis models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
contact repellency against ticks
Laboratory repellency work supports elemol as an arthropod-behavior active with measurable contact repellency against host-seeking ticks.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical studies specific to isolated elemol were verified in this pass.
- Public naming overlaps heavily with alpha-elemol, so stereochemical nuance is not handled consistently across sources.
- Most accessible activity evidence is topical-model, ecological, or materials-use work rather than inhalation or consumer-use evidence.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.